PriceTargets.com logo

CureVac - CVAC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $15.00
  • Forecasted Upside: 514.75%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.44 As of 04/18/2024 01:00 AM ET
▼ -0.13 (-5.06%)

This chart shows the closing price for CVAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CureVac Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CVAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CVAC

Analyst Price Target is $15.00
▲ +514.75% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CureVac in the last 3 months. The average price target is $15.00, with a high forecast of $24.00 and a low forecast of $8.00. The average price target represents a 514.75% upside from the last price of $2.44.

This chart shows the closing price for CVAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 investment analysts is to hold stock in CureVac. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2024GuggenheimReiterated RatingNeutralLow
8/21/2023Bank of AmericaLower TargetUnderperform ➝ Underperform$10.00 ➝ $8.00Low
6/8/2023SVB SecuritiesInitiated CoverageOutperform$13.00Low
4/26/2023JMP SecuritiesLower Target$34.00 ➝ $24.00Low
1/19/2023UBS GroupUpgradeNeutral ➝ Buy$18.00Low
1/6/2023Jefferies Financial GroupUpgradeHold ➝ Buy$21.00Low
11/17/2022JMP SecuritiesLower TargetMarket Outperform$37.00 ➝ $34.00Low
9/29/2022JMP SecuritiesReiterated RatingBuy$37.00Low
6/9/2022JMP SecuritiesReiterated RatingBuy$37.00Medium
5/26/2022JMP SecuritiesReiterated RatingBuy$37.00Low
4/22/2022JMP SecuritiesLower TargetMarket Outperform$52.00 ➝ $37.00Medium
1/21/2022Bank of AmericaDowngradeNeutral ➝ Underperform$55.00 ➝ $20.00High
1/18/2022JMP SecuritiesInitiated CoverageOutperform$52.00High
12/22/2021UBS GroupDowngradeNeutral ➝ SellHigh
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$35.00Medium
7/5/2021Evercore ISIReiterated RatingBuyMedium
7/1/2021Berenberg BankSet TargetBuy$123.00High
6/17/2021Bank of AmericaDowngradeBuy ➝ Neutral$50.00High
5/3/2021GuggenheimInitiated CoverageBuyLow
4/26/2021Credit Suisse GroupInitiated CoverageUnderperformMedium
4/26/2021GuggenheimInitiated CoverageBuyHigh
12/10/2020Credit Suisse GroupDowngradeNeutral ➝ Underperform$50.00 ➝ $47.00High
11/17/2020Berenberg BankReiterated RatingBuyLow
9/8/2020Bank of AmericaInitiated CoverageBuy$70.00High
9/8/2020Jefferies Financial GroupInitiated CoverageHold$58.00High
9/8/2020Credit Suisse GroupInitiated CoverageNeutral$68.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

CureVac logo
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Read More

Today's Range

Now: $2.44
Low: $2.44
High: $2.55

50 Day Range

MA: $3.18
Low: $2.44
High: $3.58

52 Week Range

Now: $2.44
Low: $2.44
High: $12.36

Volume

712,915 shs

Average Volume

813,024 shs

Market Capitalization

$546.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.51

Frequently Asked Questions

What sell-side analysts currently cover shares of CureVac?

The following Wall Street analysts have issued research reports on CureVac in the last year: Bank of America Co., Guggenheim, JMP Securities, and SVB Securities.
View the latest analyst ratings for CVAC.

What is the current price target for CureVac?

3 Wall Street analysts have set twelve-month price targets for CureVac in the last year. Their average twelve-month price target is $15.00, suggesting a possible upside of 514.8%. JMP Securities has the highest price target set, predicting CVAC will reach $24.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $8.00 for CureVac in the next year.
View the latest price targets for CVAC.

What is the current consensus analyst rating for CureVac?

CureVac currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CVAC, but not buy more shares or sell existing shares.
View the latest ratings for CVAC.

What other companies compete with CureVac?

Other companies that are similar to CureVac include Verve Therapeutics, Mineralys Therapeutics, Korro Bio, Olema Pharmaceuticals and Phathom Pharmaceuticals. Learn More about companies similar to CureVac.

How do I contact CureVac's investor relations team?

CureVac's physical mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The company's listed phone number is 49-70-71988-30 and its investor relations email address is [email protected]. The official website for CureVac is www.curevac.com. Learn More about contacing CureVac investor relations.